Assay development for alphalisa needed for covid-19 research in ncats TDB
Ended Purchase Order Awarded
- Contract number
- 75N95021P00112
- Awardee
-
Southern Research Institute UEI CDZJAJJHJMH5
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $27,500
Award facts
- Opportunity
-
- Assay Development for AlphaLISA needed for COVID-19 research in NCATS TDB Solicitation · 75N95021Q00073 · Posted Feb 18, 2021
- Contract value 100% obligated
- $27,500.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35205, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- National interest action
- Coronavirus COVID-19
Award details come from SAM.gov/FPDS.
About this award
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Southern Research Institute for $27,500.00. The contract is for assay development to measure the SARS-CoV-2 antiviral effect of remdesivir and the development of an AlphaLISA assay to be conducted under biosafety level 3 (BSL-3) conditions. This non-competitive contract was awarded without full and open competition due to Southern Research Institute's prior involvement in related testing. The work includes testing compound efficacy and cytotoxicity in a high-throughput 384-well plate format using VeroE6 and A549 cells. The period of performance is 3 months from the date of award. There was no set-aside designation for this contract.
Quick answers
Who was awarded contract 75N95021P00112?
75N95021P00112 was awarded to Southern Research Institute by National Institute on Drug Abuse (National Institutes of Health) on March 2, 2021.
How much is contract 75N95021P00112 worth?
The government has obligated $27,500 on 75N95021P00112.
Which agency awarded contract 75N95021P00112?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95021P00112, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95021P00112 competed?
The extent of competition for 75N95021P00112 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award